These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31819089)

  • 1. New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma.
    Wan S; Kim TH; Smith KJ; Delaney R; Park GS; Guo H; Lin E; Plegue T; Kuo N; Steffes J; Leu C; Simeone DM; Razimulava N; Parikh ND; Nagrath S; Welling TH
    Sci Rep; 2019 Dec; 9(1):18575. PubMed ID: 31819089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
    Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay.
    Zhang Y; Zhang X; Zhang J; Sun B; Zheng L; Li J; Liu S; Sui G; Yin Z
    Cancer Biol Ther; 2016 Nov; 17(11):1177-1187. PubMed ID: 27662377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma.
    Kalinich M; Bhan I; Kwan TT; Miyamoto DT; Javaid S; LiCausi JA; Milner JD; Hong X; Goyal L; Sil S; Choz M; Ho U; Kapur R; Muzikansky A; Zhang H; Weitz DA; Sequist LV; Ryan DP; Chung RT; Zhu AX; Isselbacher KJ; Ting DT; Toner M; Maheswaran S; Haber DA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1123-1128. PubMed ID: 28096363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.
    Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ
    Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
    Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
    Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.
    Chu HY; Yang CY; Yeh PH; Hsu CJ; Chang LW; Chan WJ; Lin CP; Lyu YY; Wu WC; Lee CW; Wu JK; Jiang JK; Tseng FG
    Cells; 2021 May; 10(5):. PubMed ID: 34068719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1.
    Tang Y; Lu Y; Chen Y; Luo L; Cai L; Peng B; Huang W; Liao H; Zhao L; Pan M
    J Exp Clin Cancer Res; 2019 Nov; 38(1):473. PubMed ID: 31752959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
    Ahn JC; Teng PC; Chen PJ; Posadas E; Tseng HR; Lu SC; Yang JD
    Hepatology; 2021 Jan; 73(1):422-436. PubMed ID: 32017145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved method increases sensitivity for circulating hepatocellular carcinoma cells.
    Liu HY; Qian HH; Zhang XF; Li J; Yang X; Sun B; Ma JY; Chen L; Yin ZF
    World J Gastroenterol; 2015 Mar; 21(10):2918-25. PubMed ID: 25780289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma.
    Cheng SW; Tsai HW; Lin YJ; Cheng PN; Chang YC; Yen CJ; Huang HP; Chuang YP; Chang TT; Lee CT; Chao A; Chou CY; Chan SH; Chow NH; Ho CL
    PLoS One; 2013; 8(11):e80053. PubMed ID: 24244607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
    Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
    Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
    Chen J; Cao SW; Cai Z; Zheng L; Wang Q
    Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantified postsurgical small cell size CTCs and EpCAM
    Wang L; Li Y; Xu J; Zhang A; Wang X; Tang R; Zhang X; Yin H; Liu M; Wang DD; Lin PP; Shen L; Dong J
    Cancer Lett; 2018 Jan; 412():99-107. PubMed ID: 29031565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.
    Cheng Y; Luo L; Zhang J; Zhou M; Tang Y; He G; Lu Y; Wang Z; Pan M
    J Gastrointest Surg; 2019 Dec; 23(12):2354-2361. PubMed ID: 30805878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study.
    Hamaoka M; Kobayashi T; Tanaka Y; Mashima H; Ohdan H
    PLoS One; 2019; 14(5):e0217586. PubMed ID: 31141571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
    Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
    Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis.
    Jin J; Niu X; Zou L; Li L; Li S; Han J; Zhang P; Song J; Xiao F
    Cancer Lett; 2016 Aug; 378(1):33-7. PubMed ID: 27160647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis.
    Cui K; Ou Y; Shen Y; Li S; Sun Z
    Medicine (Baltimore); 2020 Oct; 99(40):e22242. PubMed ID: 33019399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis.
    Zhang Y; Shi ZL; Yang X; Yin ZF
    World J Gastroenterol; 2014 Jan; 20(1):142-7. PubMed ID: 24415867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.